Source: FierceBiotech

Sierra Oncology: Attacking drug-resistant tumors with Sierra's struggling CHK1 blocker

Sierra Oncology deprioritized the development of its CHK1 blocker SRA737 last year, as it steered most of its dwindling resources towards developing a phase 3 myelofibrosis drug that it picked up from Gilead. Now British scientists say SRA737 has the potential to treat several tumor types as part of a combination with another protein blocker.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Stephen Dilly's photo - President & CEO of Sierra

President & CEO

Stephen Dilly

CEO Approval Rating


Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more